GlassScriptPhysician profile
Arielle Deasel
NPI 1013581974
$1,810.59
in general payments reported to CMS, 2019-2025
26 companies · $775 in 2025
The $775 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.01 · 2022: $83.05 · 2023: $506 · 2024: $383 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $259.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $221.86 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $218.92 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $134.27 | 2023-2025 | |
| Dexcom, INC. | $122.90 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $105.25 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $97.30 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $58.85 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $55.53 | 2024-2025 | Rexulti |
| Dynavax Technologies Corporation | $49.54 | 2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.20 | 2023-2025 | Jardiance, Synjardy |
| Amgen INC. | $48.14 | 2024-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $47.20 | 2023 | Austedo Xr |
| Abbvie INC. | $45.75 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.75 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $39.39 | 2024-2025 | Veozah |
| Eisai INC. | $30.56 | 2022-2023 | |
| Madrigal Pharmaceuticals | $30.13 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.41 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $23.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.60 | 2023 | Gattex |
| Phathom Pharmaceuticals, INC. | $18.11 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.22 | 2025 | Capvaxive, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $14.86 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $14.71 | 2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $14.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arielle Deasel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.